VEGF blocking therapy in the treatment of cancer

Expert Opinion on Biological Therapy

Volumn 3, Issue 2, 2003, Pages 263-276

  Glade Bender, Julia ^a   Kandel, Jessica J ^a   Yamashiro, Darrell J ^a  

^a Columbia University ^*  (United States)

Author keywords

632; Angiogenesis; Angiozyme; Avastin; Bevacizumab; CEP 7055; CP 547; HuMV833; IMC 1C11; PTK787 ZK 222584; SU11248; SU5416; SU6668; Vatalanib; VEGF; VEGF receptors; VEGF Trap; ZD6474

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; ANGIOZYME; BEVACIZUMAB; CARBOPLATIN; CHIMERIC PROTEIN; CISPLATIN; FLUOROURACIL; FOLINIC ACID; HUMV 833; IMC 1C11; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; NEUTRALIZING ANTIBODY; PACLITAXEL; SEMAXANIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN NEUTRALIZING ANTIBODY; VASCULOTROPIN TRAP; VATALANIB;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ATAXIA; BREAST CANCER; CANCER INHIBITION; CLINICAL TRIAL; COLORECTAL CANCER; DEATH; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG SAFETY; EDEMA; FATALITY; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MENSTRUATION DISORDER; MONOTHERAPY; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZATION; RASH; REVIEW; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR REGRESSION; VERTIGO; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ATAXIA;

EID: 0037391673     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.2.263     Document Type: Review

References (162)

1. SENGER DR, GALLI SJ, DVORAK AM et al.: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 219:983-985.
2. LEUNG DW, CACHIANES G, KUANG WJ, GOEDDEL DV, FERRARA N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 246:1306-1309.
3. FERRARA N: Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. (2001) 280:C1358-C1366.
4. FERRARA N, CARVER-MOORE K, CHEN H et al.: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (1996) 380:439-442.
5. CARMELIET P, FERREIRA V, BREIER G et al.: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 380:435-439.
6. TISCHER E, MITCHELL R, HARTMAN T et al.: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. (1991) 266:11947-11954.
7. CLAUSS M: Molecular biology of the VEGF and the VEGF receptor family. Semin. Thromb. Hemost. (2000) 26:561-569.
8. BATES DO, CUI TG, DOUGHTY JM et al.: VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. (2002) 62:4123-4131.
9. GRUNSTEIN J, MASBAD JJ, HICKEY R, GIORDANO F, JOHNSON RS: Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol. Cell. Biol. (2000) 20:7282-7291.
10. YU JL, RAK JW, KLEMENT G, KERBEL RS: Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. Cancer Res. (2002) 62:1838-1846.
11. GILLE H, KOWALSKI J, LI B et al.: Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem. (2001) 276:3222-3230. Demonstrates the importance of VEGFR-2, but not VEGFR-1, in endothelial cell migration and vascular permeability.
12. BREKKEN RA, OVERHOLSER JP, STASTNY VA et al.: Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. (2000) 60:5117-5124.
13. DIAS S, HATTORI K, HEISSIG B et al.: Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc. Natl. Acad. Sci. USA (2001) 98:10857-10862. Demonstration of importance of VEGF in leukaemia.
14. GERBER HP, MCMURTREY A, KOWALSKI J et al.: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. (1998) 273:30336-30343.
15. HIRATSUKA S, MINOWA O, KUNO J, NODA T, SHIBUYA M: Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA (1998) 95:9349-9354.
16. HIRATSUKA S, MARU Y, OKADA A et al.: Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. (2001) 61:1207-1213.
17. LUTTUN A, TJWA M, MOONS L et al.: Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. (2002) 8:831-840. Importance of VEGFR-1 in pathological processes from arthritis to tumour angiogenesis.
18. WENG DE, USMAN N: Angiozyme: a novel angiogenesis inhibitor. Curr. Oncol. Rep. (2001) 3:141-146.
19. LYDEN D, HATTORI K, DIAS S et al.: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. (2001) 7:1194-1201. Demonstrates the importance of circulating endothelial cells in tumour angiogenesis.
20. HIRATSUKA S, NAKAMURA K, IWAI S et al.: MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell (2002) 2:289-300.
21. RAFII S, LYDEN D, BENEZRA R, HATTORI K, HEISSIG B: Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer (2002) 2:826-835.
22. ERIKSSON U, ALITALO K: VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies. Nat. Med. (2002) 8:775-777.
23. NEUFELD G, COHEN T, SHRAGA N et al.: The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc. Med. (2002) 12:13-19.
24. LEE P, GOISHI K, DAVIDSON AJ et al.: Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish. Proc. Natl. Acad. Sci. USA (2002) 99:10470-10475.
25. SOKER S, TAKASHIMA S, MIAO HQ, NEUFELD G, KLAGSBRUN M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell (1998) 92:735-745.
26. FAKHARI M, PULLIRSCH D, ABRAHAM D et al.: Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma. Cancer (2002) 94:258-263.
27. BACHELDER RE, CRAGO A, CHUNG J et al.: Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. (2001) 61:5736-5740.
28. GERBER HP, FERRARA N: The role of VEGF in normal and neoplastic hematopoiesis. J. Mol. Med. (2003) 81:20-31.
29. BAUTZ F, RAFII S, KANZ L, MOHLE R: Expression and secretion of vascular endothelial growth factor-A by cytokine-stimulated hematopoietic progenitor cells. Possible role in the hematopoietic microenvironment. Exp. Hematol. (2000) 28:700-706.
30. ZIEGLER BL, VALTIERI M, PORADA GA et al.: KDR receptor: a key marker defining hematopoietic stem cells. Science (1999) 285:1553-1558.
31. KABRUN N, BUHRING HJ, CHOI K et al.: Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development (1997) 124:2039-2048.
32. GERBER HP, MALIK AK, SOLAR GP et al.: VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature (2002) 417:954-958.
33. HATTORI K, HEISSIG B, WU Y et al.: Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med. (2002) 8:841-849.
34. LEE SS, JOO YS, KIM WU et al.: Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin. Exp. Rheumatol. (2001) 19:321-324.
35. HOSHINO M, TAKAHASHI M, AOIKE N: Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J. Allergy Clin. Immunol. (2001) 107:295-301.
36. DETMAR M, BROWN LF, CLAFFEY KP et al.: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J. Exp. Med. (1994) 180:1141-1146.
37. AIELLO LP, PIERCE EA, FOLEY ED et al.: Suppression of retinal neovasoalarization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA (1995) 92:10457-10461.
38. KRZYSTOLIK MG, AFSHARI MA, ADAMIS AP et al.: Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. (2002) 120:338-346.
39. CREW JP, O'BRIEN T, BRADBURN M et al.: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. (1997) 57:5281-5285.
40. CHAN AS, LEUNG SY, WONG MP et al.: Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am. J. Surg. Pathol. (1998) 22:816-826.
41. VAQUERO J, ZURITA M, MORALES C, CINCU R, OYA S: Expression of vascular permeability factor in glioblastoma specimens: correlation with tumor vascular endothelial surface and peritumoral edema. J. Neurooncol. (2000) 49:49-55.
42. LINDERHOLM B, TAVELIN B, GRANKVIST K, HENRIKSSON R: Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J. Clin. Oncol. (1998) 16:3121-3128.
43. LINDERHOLM B, LINDH B, TAVELIN B, GRANKVIST K, HENRIKSSON R: p53 and vascularendothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int. J. Cancer (2000) 89:51-62.
44. TOKUNAGA T, OSHIKA Y, ABE Y et al.: Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br. J. Cancer (1998) 77:998-1002.
45. FONTANINI G, FAVIANA P, LUCCHI M et al.: A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br. J. Cancer (2002) 86:558-563.
46. SHOU Y, HIRANO T, GONG Y et al.: Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br. J. Cancer (2001) 85:1706-1712.
47. O'BYRNE KJ, KOUKOURAKIS MI, GIATROMANOLAKI A et al.: Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br. J. Cancer (2000) 82:1427-1432.
48. FUJIMOTO J, SAKAGUCHI H, AOKI I, KHATUN S, TAMAYA T: Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers. Br. J. Cancer (2001) 85:313-316.
49. PALEY PJ, STASKUS KA, GEBHARD K et al.: Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer (1997) 80:98-106.
50. EGGERT A, IKEGAKI N, KWIATKOWSKI J et al.: High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res. (2000) 6:1900-1908.
51. JACOBSEN J, RASMUSON T, GRANKVIST K, LJUNGBERG B: Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J. Urol. (2000) 163:343-347.
52. SAUTER ER, NESBIT M, WATSON JC et al.: Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin. Cancer Res. (1999) 5:775-782.
53. MASOOD R, CAI J, ZHENG T et al.: Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood (2001) 98:1904-1913.
54. STRIZZI L, CATALANO A, VIANALE G et al.: Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J. Pathol. (2001) 193:468-475.
55. BOOCOCK CA, CHARNOCK-JONES DS, SHARKEY AM et al.: Expression of vascular endothelial growth factor and its receptors fit and KDR in ovarian carcinoma. J. Natl. Cancer Inst. (1995) 87:506-516.
56. JACKSON MW, ROBERTS JS, HECKFORD SE et al.: A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res. (2002) 62:854-859.
57. BACHELDER RE, WENDT MA, MERCURIO AM: Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res. (2002) 62:7203-7206.
58. FOSS HD, ARAUJO I, DEMEL G et al.: Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J. Pathol. (1997) 183:44-50.
59. BELLAMY WT. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin. Oncol. (2001) 28:551-559.
60. AGUAYO A, KANTARJIAN HM, ESTEY EH et al.: Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer (2002) 95:1923-1930.
61. DIAS S, HATTORI K, ZHU Z et al.: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. (2000) 106:511-521.
62. GILES FJ: The emerging role of angiogenesis inhibitors in hematologic malignancies. Oncology (Huntingt) (2002) 16:23-29.
63. HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 86:353-364.
64. FANG J, YAN L, SHING Y, MOSES MA: Hif-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res. (2001) 61:5731-5735.
65. BERGERS G, BREKKEN R, MCMAHON G et al.: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. (2000) 2:737-744.
66. INOUE M, HAGER JH, FERRARA N, GERBER HP, HANAHAN D: VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell (2002) 1:193-202. Elegant paper on the role of VEGF in the angiogenic switch.
67. KRAFT A, WEINDEL K, OCHS A et al.: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer (1999) 85:178-187.
68. ZEBROWSKI BK, YANO S, LIU W et al.: Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin. Cancer Res. (1999) 5:3364-3368.
69. NAGY JA, MASSE EM, HERZBERG KT et al.: Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res. (1995) 55:360-368.
70. KE L, QU H, NAGY JA et al.: Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor. Eur. J. Cancer (1996) 32A:2467-2473.
71. LUO JC, TOYODA M, SHIBUYA M: Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res. (1998) 58:2594-2600.
72. KIM KJ, LI B, WINER J et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 362:841-844. First paper to demonstrate the essential role of VEGF in tumour angiogenesis by use of an anti-VEGF neutralising antibody.
73. PRESTA LG, CHEN H, O'CONNOR SJ et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. (1997) 57:4593-4599.
74. ASANO M, YUKITA A, SUZUKI H: Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn J. Cancer Res. (1999) 90:93-100.
75. LIN P, SANKAR S, SHAN S et al.: Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. (1998) 9:49-58.
76. HOLASH J, DAVIS S, PAPADOPOULOS N et al.: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA (2002) 99:11393-11398.
77. HUANG J, MOORE J, SOFFER S et al.: Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J. Pediatr. Surg. (2001) 36:357-361.
78. PREWETT M, HUBER J, LI Y et al.: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. (1999) 59:5209-5218.
79. FONG TA, SHAWVER LK, SUN L et al.: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. (1999) 59:99-106.
80. WEDGE SR, OGILVIE DJ, DUKES M et al.: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. (2002) 62:4645-4655.
81. WOOD JM, BOLD G, BUCHDUNGER E et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. (2000) 60:2178-2189.
82. ARORA N, MASOOD R, ZHENG T et al.: Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res. (1999) 59:183-188.
83. IM SA, GOMEZ-MANZANO C, FUEYO J et al.: Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res. (1999) 59:895-900.
84. KAMIYAMA M, ICHIKAWA Y, ISHIKAWA T et al.: VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. Cancer Gene Ther. (2002) 9:197-201.
85. SALEH M, STACKER SA, WILKS AF: Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. (1996) 56:393-401.
86. IM SA, KIM JS, GOMEZ-MANZANO C et al.: Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br. J. Cancer (2001) 84:1252-1257.
87. BECKER CM, FARNEBO FA, IORDANESCU I et al.: Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor flk1. Cancer Biol. Ther. (2002) 1:548-553.
88. BORGSTROM P, GOLD DP, HILLAN KJ, FERRARA N: Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. (1999) 19:4203-4214.
89. BORGSTROM P, BOURDON MA, HILLAN KJ, SRIRAMARAO P, FERRARA N: Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate (1998) 35:1-10.
90. GERBER HP, KOWALSKI J, SHERMAN D, EBERHARD DA, FERRARA N: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. (2000) 60:6253-6258. Demonstrates the role of host VEGF in tumour angiogenesis.
91. ROWE DH, HUANG J, KAYTON ML et al.: Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J. Pediatr. Surg. (2000) 35:30-32; Discussion:32-33.
92. MESIANO S, FERRARA N, JAFFE RB: Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am. J. Pathol. (1998) 153:1249-1256.
93. GORDON MS, MARGOLIN K, TALPAZ M et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. (2001) 19:843-850.
94. YANG JC, HAWORTH L, STEINBERG SM, ROSENBERG SA, NOVOTNY W: A randomized double-blind placebo-controlled trial of bevacizumab (and-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc. Am. Soc. Clin. Oncol. (2002) 20:15 (Abstract).
95. IGARASHI H, ESUMI M, ISHIDA H, OKADA K: Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer (2002) 95:47-53.
96. LANGMUIR VK, COBLEIGH MA, HERBST RS et al.: Successful long-term therapy with bevacizumab (Avastin) in solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 20:32 (Abstract).
97. DEVORE R, FEHRENBACHER L, HERBST R et al.: A randomized Phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paditaxel (CP) to CP alone in patients with Stage IIIB/IV NSCLC. Proc. Am. Soc. Clin. Oncol. (2000) 18:1896 (Abstract).
98. NOVOTNY WF, HOLMGREN E, GRIFFING S et al.: Identification of squamous cell histology and central, cavitary tumors as possible risk factors for pulmonary hemorrhage (PH) in patients with advanced NSCLC receiving bevacizumab (BV). Proc. Am. Soc. Clin. Oncol. (2001) 19:1318 (Abstract).
99. JOHNSON DH, DEVORE R, KABBINAVAR F et al.: Carboplatin (C) + Paditaxel (T) + RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc. Am. Soc. Clin. Oncol. (2001) 19:1256 (Abstract).
100. KABBINAVAR FF, JOHNSON D, LANGMUIR VK, HOLMGREN E, BERGSLAND E: Patterns of tumor progression during therapy with bevacizumab (BV) and chemotherapy (CT) for metastatic colorectal cancer (MCRC) and advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2001) 19:1105 (Abstract).
101. KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al.: Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. (2003) 21:60-65.
102. JAYSON GC, ZWEIT J, JACKSON A et al.: Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J. Natl. Cancer Inst. (2002) 94:1484-1493.
103. KIM ES, SERURA A, HUANG J et al.: Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. USA (2002) 99:11399-11404.
104. DUPONT J, PEZZULLI S, GORDON MS et al.: A phase I study of the novel high affinity VEGF blocker VEGF trap in patients with refractory solid tumors and lymphoma. Eur. J. Cancer (2002) 38(Suppl. 7):81 (Abstract).
105. ZHU Z, LU D, KOTANIDES H et al.: Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody. Cancer Lett. (1999) 136:203-213.
106. HUNT S: Technology evaluation: IMC-1C11, ImClone Systems. Curr. Opin. Mol. Ther. (2001) 3:418-424.
107. KUNKEL P, ULBRICHT U, BOHLEN P et al.: Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monodonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. (2001) 61:6624-6628.
108. KLEMENT G, BARUCHEL S, RAK J et al.: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. (2000) 105:R15-R24. Demonstrates increased efficacy with combination therapy with VEGF blockade and low dose metronomic chemotherapy.
109. BROWDER T, BUTTERFIELD CE, KRALING BM et al.: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. (2000) 60:1878-1886. Introduces the concept of metronomic chemotherapy to inhibit angiogenesis.
110. HANAHAN D, BERGERS G, BERGSLAND E: Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice [comment]. J. Clin. Invest. (2000) 105:1045-1047.
111. POSEY J, NG T, YANG B et al.: A phase I trial of an anti-KDR (VEGFR) chimeric antibody in patient with liver metastases in colorectal cancer (CRC). Proc. Am. Soc. Clin. Oncol. (2002) 20:63 (Abstract).
112. SUN L, TRAN N, LIANG C et al.: Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, an PDGF receptor tyrosine kinases. J. Med. Chem. (1999) 42:5120-5130.
113. SHAHEEN RM, DAVIS DW, LIU W et al.: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. (1999) 59:5412-5416.
114. LAIRD AD, VAJKOCZY P, SHAWVEK LK et al.: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. (2001) 60:4152-4160.
115. ANGELOV L, SALHIA B, RONCARI L, MCMAHON G, GUHA A: Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res. (1999) 59:5536-5541.
116. LAIRD AD, CHRISTENSEN JG, LI G et al.: SU6668 inhibits Flk-1/KDR and and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J. (2002) 16:681-690.
117. ROSEN L, MULAY M, MAYERS A et al.: Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. (1999) 18:161 (Abstract).
118. O'DONNELL A, TRIGO J, BANERJI U et al.: A Phase I trial of the VEGF inhibitor SU5416, incorporating dynamic contrast MRI assessment of vascular permeability. Proc. Am. Soc. Clin. Oncol. (2000) 18:685 (Abstract).
119. CROPP G, ROSEN L, MULAY M, LANGECKER P, HANNAH A: Pharmacokinetics and pharmacodynamics of SU5416 in a Phase I, dose escalating trial in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. (1999) 17:(Abstract).
120. STOPECK A, SHELDON M, VAHEDIAN M et al.: Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin. Cancer Res. (2002) 8:2798-2805.
121. GAJEWSKI TF, FLICKINGER S, HEIMANN R et al.: Phase II Study of the anti-angiogenic Flk-1 tyrosine kinase inhibitor SU5416 in melanoma: initial results. Proc. Am. Soc. Clin. Oncol. (2001) 19:1436 (Abstract).
122. FIEDLER WM, TINNEFELD H, MENDE T et al.: A Phase II study with SU5416 in patients with C-Kit positive AML. Proc. Am. Soc. Clin. Oncol. (2001) 19:1148 (Abstract).
123. MILLER LL, ELFRING GL, HANNAH AL et al.: Efficacy results of a Phase I/II study of SU5416 (S)/5-fluorouracil (F)/leucovorin (L) relative to results in random subsets of similar patients (Pts) from a Phase III study of irinotecan (C)/F/L or F/L alone in the therapy of previously untreated metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. (2001) 19:571 (Abstract).
124. ROSEN P, AMADO R, HECHT J et al.: A Phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2000) 18:5D (Abstract).
125. KUENEN BC, ROSEN L, SMIT EF et al.: Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. (2002) 20:1657-1667.
126. KUENEN BC, LEVI M, MEIJERS JC et al.: Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler. Thromb. Vasc. Biol. (2002) 22:1500-1505.
127. ROSEN LS, ROSEN PJ, KABBINAVAR F et al.: Phase I experience with SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. (2001) 19:383 (Abstract).
128. BRITTEN D, ROSEN LS, KABBINAVAR F et al.: Phase I trial of SU6668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancers. Proc. Am. Soc. Clin. Oncol. (2002) 20:1922 (Abstract).
129. KUENEN B, RUIJTER R, HOEKMAN K et al.: Dose finding study of SU6668 given thrice daily by oral route under fed conditions in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. (2002) 20:437 (Abstract).
130. BRAHMER JR, KELSEY S, SCIGALLA P et al.: A phase I study of SU6668 in patients with refractory solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 20:335 (Abstract).
131. GRASSELLI G, BASELGA J, SESSA C et al.: Dose-escalation and pharmacologic study of oral SU-006668 in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 20:67 (Abstract).
132. MENDEL DB, LAIRD AD, XIN X et al.: Development of a preclinical pharmacokinetic/pharmacodynamic relationship for the angiogenesis inhibitor SU11248, a selective inhibitor of VEGF and PDGF receptor tyrosine kinases in clinical development. Proc. Am. Soc. Clin. Oncol. (2002) 20:94 (Abstract).
133. RAYMOND E, FAIVRE S, VERA K et al.: First results of a phase I and pharmacokinetic study of SU011248, a novel oral anti-angiogenic agent, in patients with advanced solid tumours. Eur. J. Cancer (2002) 38(Suppl. 7):17 (Abstract).
134. DREVS J, HOFMANN I, HUGENSCHMIDT H et al.: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. (2000) 60:4819-4824.
135. LIN B, PODAR K, GUPTA D et al.: The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. (2002) 62:5019-5026.
136. YANO S, HERBST RS, SHINOHARA H et al.: Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin. Cancer Res. (2000) 6:957-965.
137. HESS C, VUONG V, HEGYI I et al.: Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br. J. Cancer (2001) 85:2010-2016.
138. THOMAS A, MORGAN B, DREVS J et al.: Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 Phase 1 studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2001) 19:279 (Abstract).
139. DREVS J, MROSS K, FUXIUS S et al.: A Phase-1 dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor-inhibitor PTK787/ZK222584 (PTK/ZK) in patients with liver metastasis of advanced cancer. Proc. Am. Soc. Clin. Oncol. (2001) 19:398 (Abstract).
140. YUNG WKA, FRIEDMAN H, JACKSON E et al.: A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma. Proc. Am. Soc. Clin. Oncol. (2002) 20:315 (Abstract).
141. CARLOMAGNO F, VITAGLIANO D, GUIDA T et al.: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. (2002) 62:7284-7290.
142. BASSER R, HURWITZ H, BARGE A et al.: Phase 1 pharmacokinetic and biological study of the angiogenesis inhibitor, ZD6474, in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2001) 19:396 (Abstract).
143. HURWITZ H, HOLDEN SN, ECKHARDT SG et al.: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 20:325 (Abstract).
144. THOMAS A, MORGAN B, DECATRIS A et al.: A Phase I study of the oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer. Eur. J. Cancer (2002) 38(Suppl. 7):77 (Abstract).
145. ROBERTS WG, JANI J, BEEBE J et al.: Preclinical development of CP-547,632, a novel VEGFR-2 inhibitor for cancer therapy. Proc. Am. Soc. Clin. Oncol. (2002) 20:473 (Abstract).
146. TOLCHER AW, O'LEARY JJ, DEBONO JS et al.: A phase I and biologic correlative study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients (pts) with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 20:334 (Abstract).
147. PAVCO PA, BOUHANA KS, GALLEGOS AM et al.: Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Cancer Res. (2000) 6:2094-2103.
148. SANDBERG JA, PARKER VP, BLANCHARD KS et al.: Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J. Clin. Pharmacol. (2000) 40:1462-1469.
149. USMAN N, BLATT LM: Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J. Clin. Invest. (2000) 106:1197-1202.
150. USMAN N, VENOOKA A, HURWITZ H et al.: A Phase II study of ANGIOZYME in combination with 5-fluorouracil, leucovorin and irinotecan in the treatment of metastatic colorectal cancer patients. Eur. J. Cancer (2002) 38(Suppl. 7):72 (Abstract).
151. ROWE DH, HUANG J, LI J et al.: Suppression of primary tumor growth in
152. KIM E, MOORE J, HUANG J et al.: All angiogenesis is not the same: distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. J. Pediatr. Surg. (2001) 36:287-290.
153. SOFFER SZ, KIM E, HUANG J et al.: Resistance of a VEGF-producing tumor to anti-VEGF antibody: unimpeded growth of human rhabdoid tumor xenografts. J. Pediatr. Surg. (2002) 37:528-532.
154. HORMBREY E, GILLESPIE P, TURNER K et al.: A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin. Exp. Metastasis (2002) 19:651-663.
155. BYRNE GJ, BUNDRED NJ: Surrogate markers of tumoral angiogenesis. Int. J. Biol. Markers (2000) 15:334-339.
156. BYRNE GJ, GHELLAL A, IDDON J et al.: Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J. Natl. Cancer Inst. (2000) 92:1329-1336.
157. BRAYBROOKE JP, O'BYRNE KJ, PROPPER DJ et al.: A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin. Cancer Res. (2000) 6:4697-4704.
158. KLEMENT G, HUANG P, MAYER B et al.: Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res. (2002) 8:221-232.
159. BOEHM T, FOLKMAN J, BROWDER T, O'REILLY MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 390:404-407.
160. KERBEL RS, YU J, TRAN J et al.: Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. (2001) 20:79-86.
161. HOLASH J, MAISONPIERRE PC, COMPTON D et al.: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (1999) 284:1994-1998. Demonstrates that tumours can co-opt existing vascular to sustain tumour growth.
162. YU JL, RAK JW, COOMBER BL, HICKLIN DJ, KERBEL RS: Effect of p53 status on tumor response to antiangiogenic therapy. Science (2002) 295:1526-1528. Demonstrates the possibility of resistance to antiangiogenic therapy.